October 31, 2020 : Issue #1076

TOP STORIES — Diabetes News and Research

Impact of Physical Activity and Metformin on Postprandial Glucose

Skim Milk vs. Whole Milk: What’s the Healthier Option?

Role of Magnesium in Type 2 Diabetes and Stroke

Living in the heat of Florida you learn very quickly what happens if your magnesium levels get too low. Riding 40-50 miles without taking in enough magnesium will leave you with leg cramps, increased heart rate and nausea. Because it is so hard to eat enough foods to boost your levels, most of us take magnesium supplements. Just like with many medications and supplements, we are learning that there is often an added benefit that magnesium provides.

This week our intern, Mia Flowers, PharmD. Candidate of FAMU College of Pharmacy, has a great article on how proper magnesium levels can reduce the onset of type 2 diabetes and stroke.

Click here to learn about the science and what dosing levels you need.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Lifestyle modifications as first-line treatment have paramount importance on the quality of life.

Does the fat content of dairy products play a role in the development of metabolic syndrome (MetS)?

Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents. 

Type 2 diabetes is characterized by accelerated cognitive decline and higher dementia risk. Controversy exists regarding the impact of metformin, associated with both increased and decreased dementia rates. This study’s objective was to determine the association of metformin use with incident dementia and cognitive decline over six years in diabetes participants compared with those not receiving metformin and those without diabetes.

This prospective observational study was conducted of N = 1,037 community-dwelling older participants without dementia aged 70–90 years at baseline (the Sydney Memory and Ageing Study). Exclusion criteria were dementia, major neurological or psychiatric disease, or progressive malignancy. Neuropsychological testing measured cognitive function every two years; a battery of tests measured executive function, memory, attention/speed, language, and visuospatial function individually. The result of n = 1,037, 123 had diabetes; 67 received metformin (DM+MF) and were demographically similar to those who did not (DM-noMF) and participants without diabetes (no-DM). DM+MF had significantly slower global cognition and executive function decline compared with DM-noMF. Incident dementia was considerably higher in DM-noMF compared with DM+MF (odds ratio 5.29 [95% CI 1.17–23.88]; P = 0.05).

The study results determined that older people with diabetes receiving metformin have slower cognitive decline and lower dementia risk. Diabetes Care 2020 Nov; 43(11): 2691-2701

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy

Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University  School of Pharmacy 

Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy

Lynn C. Luu, PharmD Candidate 2022, Washington State University

Arjay Mendoza, PharmD Candidate, University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences 

Leyany Feijoo Ramos, PharmD. Candidate, LECOM School of Pharmacy

Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com